SUMMARY OF CHANGES:
INSTRUMENT NOS. 94 to 115 OF 2015
Statements of Principles (SoPs) Nos. 94 to 113 of 2015 were signed by the Chairperson of the
Repatriation Medical Authority (the RMA) on 21 August 2015. Amendment SoPs Nos. 114 &
115 of 2015 were signed by the Chairperson on 31 August 2015.
The Instruments have been lodged and registered with the Federal Register of Legislative
Instruments, pursuant to Section 24 of the Legislative Instruments Act 2003 (the LIA). The day
of commencement as specified in each of the Statements of Principles is 21 September 2015.
In accordance with the LIA, the Attorney-General’s Department tables the Instruments in both
Houses of Parliament. The Instruments and the associated Explanatory Statements registered
with the Federal Register of Legislative Instruments are available from:
http://www.comlaw.gov.au.
Copies of each Instrument, the associated Explanatory Statement and a list of references relating
to each Instrument, are available in accordance with the Veterans' Entitlements Act 1986 (the
VEA), on written request from the RMA Secretariat.
The Authority has introduced significant change to the format of the Statements of Principles
determined by it under subsections 196B(2) and 196B(3) of the VEA. The changes were
introduced to make the relationship between the provisions of the Statements of Principles and
the legislative framework for their creation and use clearer and to make them more accessible
to users. The 'User Guide to the RMA Statements of Principles' explains the meaning and
purpose of each section of the new template. This document is also available on the Authority's
website http://www.rma.gov.au.
For further information contact:
The Registrar
Repatriation Medical Authority
GPO Box 1014
Brisbane Qld 4001
T +61 7 3815 9404
F +61 7 3815 9412
E info@rma.gov.au
31 August 2015
Page 1 of 11
SUMMARY OF CHANGES
Instr. No.
Title
REVOCATIONS
Date of effect
21/09/2015
ICD-10-AM Codes
94 & 95/2015
fracture
Nil
96 & 97/2015
Achilles tendinopathy & 21/09/2015
bursitis
M76.6
98 & 99/2015
hallux valgus
21/09/2015
M20.1
100 & 101/2015
lipoma
21/09/2015
D17
102 & 103/2015
malignant melanoma of
the skin
21/09/2015
Nil
104 & 105/2015
mesothelioma
21/09/2015
C45
106 & 107/2015
ingrowing nail
21/09/2015
L60.0
108 & 109/2015
Meniere's disease
21/09/2015
H81.0
110 & 111/2015
external burn
21/09/2015
Nil
112 & 113/2015
hepatitis E
21/09/2015
B17.2
lipoma
21/09/2015
Nil
AMENDMENTS
114 & 115/2015
Page 2 of 11
SUMMARY OF CHANGES
94 & 95/2015
Page 3 of 11
fracture
These Instruments result from an investigation notified by the Authority in the Government
Notices Gazette of 2 May 2012 concerning fracture in accordance with section 196G of the
VEA. The investigation involved an examination of the sound medical-scientific evidence
now available to the Authority, including the sound medical-scientific evidence it has
previously considered.
The contents of these Instruments are in similar terms as the revoked Instruments. Comparing
these Instruments and the revoked Instruments, the differences include:
For RH SoP (Instrument No. 94/2015)

adopting the latest revised Instrument format, which commenced in 2015;

specifying a day of commencement for the Instrument in section 2;

revising factors in subsections 9(1) & 9(15) concerning 'physical trauma';

new factor in subsection 9(3) concerning 'significant biomechanical abnormality',
for stress fracture of the lower limb only;

revising factors in subsections 9(1) & 9(13) concerning 'physical trauma';

new factor in subsection 9(3) concerning 'significant biomechanical abnormality',
for stress fracture of the lower limb only;

revising factors in subsections 9(8) & 9(16) concerning 'osteomyelitis';

new factors in subsections 9(11) & 9(17) concerning 'osteogenesis imperfecta';

new factor in subsection 9(12)(a) concerning 'smoking', for minimal trauma fracture
only;

new factor in subsection 9(12)(b) concerning 'alcohol' for minimal trauma fracture
only;

new factor in subsection 9(12)(c) concerning 'diabetes mellitus', for minimal trauma
fracture only;

new factor in subsection 9(12)(d) concerning 'human immunodeficiency virus', for
minimal trauma fracture only;

new factor in subsection 9(12)(e) concerning 'glucocorticoid drugs', for minimal
trauma fracture only;

new factor in subsection 9(12)(f) concerning 'rheumatoid arthritis', for minimal
trauma fracture only;

new factor in subsection 9(12)(g) concerning 'an aromatase inhibitor', for minimal
trauma fracture only;

new factor in subsection 9(12)(h) concerning 'a proton pump inhibitor', for minimal
trauma fracture only;

new factor in subsection 9(12)(i) concerning 'hepatitis C virus', for minimal trauma
fracture only;

new factor in subsection 9(18) concerning 'diabetes mellitus';

new factor in subsection 9(19) concerning 'human immunodeficiency virus';

new factor in subsection 9(20) concerning 'glucocorticoid drugs';

new factor in subsection 9(21) concerning 'rheumatoid arthritis';

new factor in subsection 9(22) concerning 'an aromatase inhibitor';

new definitions of 'alcohol', 'chronic infection with the hepatitis C virus',
'glucocorticoid drug as specified', 'minimal trauma fracture', 'MRCA', 'pack-years
of cigarettes, or the equivalent thereof in other tobacco products', 'significant
biomechanical abnormality' and 'VEA' in Schedule 1 - Dictionary; and

revising the definition of 'relevant service' in Schedule 1 – Dictionary.
For BoP SoP (Instrument No. 95/2015)

adopting the latest revised Instrument format, which commenced in 2015;

specifying a day of commencement for the Instrument in section 2;

revising factors in subsections 9(1) & 9(13) concerning 'physical trauma';

new factor in subsection 9(3) concerning 'significant biomechanical abnormality',
for stress fracture of the lower limb only;

revising factors in subsections 9(8) & 9(16) concerning 'osteomyelitis';

new factors in subsections 9(11) & 9(17) concerning 'osteogenesis imperfecta';

new factor in subsection 9(12)(a) concerning 'smoking', for minimal trauma fracture
only;
SUMMARY OF CHANGES

96 & 97/2015
Achilles
tendinopathy
and bursitis
new factor in subsection 9(12)(b) concerning 'alcohol', for minimal trauma fracture
only;

new factor in subsection 9(12)(c) concerning 'diabetes mellitus', for minimal trauma
fracture only;

new factor in subsection 9(12)(d) concerning 'human immunodeficiency virus', for
minimal trauma fracture only;

new factor in subsection 9(12)(e) concerning 'glucocorticoid drugs', for minimal
trauma fracture only;

new factor in subsection 9(12)(f) concerning 'rheumatoid arthritis', for minimal
trauma fracture only;

new factor in subsection 9(12)(g) concerning 'an aromatase inhibitor', for minimal
trauma fracture only;

new factor in subsection 9(18) concerning 'diabetes mellitus';

new factors in subsection 9(19) concerning 'human immunodeficiency virus';

new factor in subsection 9(20) concerning 'glucocorticoid drugs';

new factor in subsection 9(21) concerning 'rheumatoid arthritis';

new factor in subsection 9(22) concerning 'an aromatase inhibitor';

new definitions of 'alcohol', 'glucocorticoid drug as specified', 'minimal trauma
fracture', 'MRCA', 'pack-years of cigarettes, or the equivalent thereof in other
tobacco products', 'significant biomechanical abnormality' and 'VEA' in Schedule 1
- Dictionary; and

revising the definition of 'relevant service' in Schedule 1 – Dictionary.
The determining of these Instruments finalises the investigation in relation to fracture
as advertised in the Government Notices Gazette of 2 May 2012.
These Instruments result from an investigation notified by the Authority in the Government
Notices Gazette of 31 October 2012 concerning Achilles tendinopathy and bursitis in
accordance with section 196G of the VEA. The investigation involved an examination of the
sound medical-scientific evidence now available to the Authority, including the sound
medical-scientific evidence it has previously considered.
The contents of these Instruments are in similar terms as the revoked Instruments. Comparing
these Instruments and the revoked Instruments, the differences include:
For RH SoP (Instrument No. 96/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the definition of 'Achilles tendinopathy' in subsection 7(2);
 new factors in subsections 9(1) & 9(12) concerning 'running or jogging';
 revising factors in subsections 9(2) & 9(13) concerning 'weight bearing exercise';
 new factors in subsections 9(3) & 9(14) concerning 'increasing the frequency, duration or
intensity of weight bearing activity';
 revising factors in subsections 9(4) & 9(15) concerning 'systemic arthritic diseases';
 revised factors in subsections 9(5) & 9(16) concerning 'significant biomechanical
abnormality';
 new factors in subsections 9(8) & 9(19) concerning 'glucocorticoid drugs';
 new factor in subsection 9(20) concerning 'glucocorticoid injection', for clinical
worsening only;
 new factors in subsection 9(9) & 9(21) concerning 'being obese';
 new factors in subsection 9(10) & 9(22) concerning 'diabetes mellitus';
 new factors in subsection 9(11) & 9(23) concerning 'an aromatase inhibitor';
 new definitions of 'being obese', 'glucocorticoid drug as specified', 'MRCA', 'specified list
of systemic arthritic diseases' and 'VEA' in Schedule 1 - Dictionary;
 revising the definitions of 'relevant service' and 'significant biomechanical abnormality'
in Schedule 1 - Dictionary; and
 deleting the definitions of 'a systemic arthritic disease' and 'reactive arthropathy'.
For BoP SoP (Instrument No. 97/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the definition of 'Achilles tendinopathy' in subsection 7(2);
Page 4 of 11
SUMMARY OF CHANGES
98 & 99/2015
100 &
101/2015
Page 5 of 11
hallux valgus
lipoma
 new factors in subsections 9(1) & 9(11) concerning 'running or jogging';
 revising factors in subsections 9(2) & 9(12) concerning 'weight bearing exercise';
 new factors in subsections 9(3) & 9(13) concerning 'increasing the frequency, duration or
intensity of weight bearing activity';
 revising factors in subsections 9(4) & 9(14) concerning 'systemic arthritic diseases';
 revised factors in subsections 9(5) & 9(15) concerning 'significant biomechanical
abnormality';
 new factors in subsections 9(7) & 9(17) concerning 'glucocorticoid drugs';
 new factor in subsection 9(18) concerning 'glucocorticoid injection', for clinical
worsening only;
 new factors in subsections 9(8) & 9(19) concerning 'being obese';
 new factors in subsections 9(9) & 9(20) concerning 'diabetes mellitus';
 new factors in subsections 9(10) & 9(21) concerning 'an aromatase inhibitor';
 new definitions of 'being obese', 'glucocorticoid drug as specified', 'MRCA', 'specified list
of systemic arthritic diseases' and 'VEA' in Schedule 1 - Dictionary;
 revising the definitions of 'relevant service' and 'significant biomechanical abnormality'
in Schedule 1 - Dictionary; and
 deleting the definitions of 'a systemic arthritic disease' and 'reactive arthropathy'.
The determining of these Instruments finalises the investigation in relation to Achilles
tendinopathy and bursitis as advertised in the Government Notices Gazette of
31 October 2012.
These Instruments result from an investigation notified by the Authority in the Government
Notices Gazette of 31 October 2012 concerning hallux valgus in accordance with section
196G of the VEA. The investigation involved an examination of the sound medical-scientific
evidence now available to the Authority, including the sound medical-scientific evidence it
has previously considered.
The contents of these Instruments are in similar terms as the revoked Instruments. Comparing
these Instruments and the revoked Instruments, the differences include:
For RH SoP (Instrument No. 98/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the definition of 'hallux valgus' in subsection 7(2);
 revising factors in subsections 9(1) & 9(8) concerning 'footwear';
 new factors in subsections 9(5) & 9(12) concerning 'a tumour that involves the second
metatarsal bone';
 revising factors in subsections 9(6) & 9(13) concerning 'surgery';
 new definitions of 'MRCA', 'surgery as specified' and 'VEA' in Schedule 1 - Dictionary;
 revising the definitions of 'relevant service' and 'trauma to the affected forefoot' in
Schedule 1 - Dictionary; and
 deleting the definition of 'surgery to the affected region'.
For BoP SoP (Instrument No. 99/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the definition of 'hallux valgus' in subsection 7(2);
 revising factors in subsections 9(1) & 9(7) concerning 'footwear';
 new factors in subsections 9(4) & 9(10) concerning 'a tumour that involves the second
metatarsal bone';
 revising factors in subsections 9(5) & 9(11) concerning 'surgery';
 new definitions of 'MRCA', 'surgery as specified' and 'VEA' in Schedule 1 - Dictionary;
 revising the definitions of 'relevant service' and 'trauma to the affected forefoot' in
Schedule 1 - Dictionary; and
 deleting the definition of 'surgery to the affected region'.
The determining of these Instruments finalises the investigation in relation to hallux
valgus as advertised in the Government Notices Gazette of 31 October 2012.
These Instruments result from an investigation notified by the Authority in the Government
Notices Gazette of 31 October 2012 concerning lipoma in accordance with section 196G of
the VEA. The investigation involved an examination of the sound medical-scientific
SUMMARY OF CHANGES
evidence now available to the Authority, including the sound medical-scientific evidence it
has previously considered.
The contents of these Instruments are in similar terms as the revoked Instruments. Comparing
these Instruments and the revoked Instruments, the differences include:
102 &
103/2015
Page 6 of 11
malignant
melanoma of
the skin
For RH SoP (Instrument No. 100/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the definition of 'lipoma' in subsection 7(2);
 new factor in subsection 9(1) concerning 'alcohol use disorder', for benign symmetrical
lipomatosis only;
 new factor in subsection 9(2) concerning 'hepatic steatosis or steatohepatitis', for hepatic
lipoma only;
 new definitions of 'benign symmetrical lipomatosis', 'hepatic steatosis', 'MRCA' and
'VEA' in Schedule 1 - Dictionary;
 revising the definition of 'relevant service' in Schedule 1 – Dictionary.
For BoP SoP (Instrument No. 101/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the definition of 'lipoma' in subsection 7(2);
 new factor in subsection 9(1) concerning 'alcohol use disorder', for benign symmetrical
lipomatosis only;
 new definitions of 'benign symmetrical lipomatosis', 'MRCA' and 'VEA' in Schedule 1 Dictionary;
 revising the definition of 'relevant service' in Schedule 1 – Dictionary.
The determining of these Instruments finalises the investigation in relation to lipoma
as advertised in the Government Notices Gazette of 31 October 2012.
These Instruments result from an investigation notified by the Authority in the Government
Notices Gazette of 31 October 2012 concerning malignant melanoma of the skin in
accordance with section 196G of the VEA. The investigation involved an examination of the
sound medical-scientific evidence now available to the Authority, including the sound
medical-scientific evidence it has previously considered.
The contents of these Instruments are in similar terms as the revoked Instruments. Comparing
these Instruments and the revoked Instruments, the differences include:
For RH SoP (Instrument No. 102/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the definition of 'malignant melanoma of the skin' in subsection 7(2);
 revising the factor in subsection 9(1) concerning 'sunburn';
 revising the factor in subsection 9(2) concerning 'sunlight or ultraviolent light exposure';
 new factor in subsection 9(3) concerning 'ultraviolet radiation exposure from an
ultraviolet-emitting tanning device';
 new factor in subsection 9(4) concerning 'solid organ or bone marrow transplantation';
 revising the factor in subsection 9(5) concerning 'an immunosuppressive drug';
 revising the factor in subsection 9(7) concerning 'human immunodeficiency virus';
 new factor in subsection 9(8) concerning 'non-Hodgkin's lymphoma or chronic
lymphocytic leukaemia/small cell lymphoma';
 new factor in subsection 9(9) concerning 'Parkinson's disease';
 new factor in subsection 9(10) concerning 'a scar involving the affected site, where the
scar is the result of a thermal or chemical burn';
 new definitions of 'equivalent sunlight exposure in other latitude zones', 'MRCA',
'sunburn as specified', 'tropical area', 'unprotected skin' and 'VEA' in Schedule 1 Dictionary;
 revising the definitions of 'immunosuppressive drug' and 'relevant service' in Schedule 1
- Dictionary; and
 deleting the definitions of 'solar UV exposure factor ratio', 'solar UV exposure factor ratio
formula' and 'sunburn'.
For BoP SoP (Instrument No. 103/2015)
SUMMARY OF CHANGES






104 &
105/2015
106 &
107/2015
Page 7 of 11
mesothelioma
ingrowing nail
adopting the latest revised Instrument format, which commenced in 2015;
specifying a day of commencement for the Instrument in section 2;
revising the definition of 'malignant melanoma of the skin' in subsection 7(2);
revising the factor in subsection 9(1) concerning 'sunburn';
revising the factor in subsection 9(2) concerning 'sunlight or ultraviolent light exposure';
new factor in subsection 9(3) concerning 'ultraviolet radiation exposure from an
ultraviolet-emitting tanning device';
 new factor in subsection 9(4) concerning 'solid organ or bone marrow transplantation';
 revising the factor in subsection 9(5) concerning 'an immunosuppressive drug';
 new factor in subsection 9(7) concerning 'human immunodeficiency virus';
 new factor in subsection 9(8) concerning 'non-Hodgkin's lymphoma or chronic
lymphocytic leukaemia/small cell lymphoma';
 new factor in subsection 9(9) concerning 'Parkinson's disease';
 new definitions of 'equivalent sunlight exposure in other latitude zones', 'MRCA',
'sunburn as specified', 'tropical area', 'unprotected skin' and 'VEA' in Schedule 1 Dictionary;
 revising the definitions of 'immunosuppressive drug' and 'relevant service' in Schedule 1
- Dictionary; and
 deleting the definitions of 'solar UV exposure factor ratio', 'solar UV exposure factor ratio
formula' and 'sunburn'.
The determining of these Instruments finalises the investigation in relation to
malignant melanoma of the skin as advertised in the Government Notices Gazette of
31 October 2012.
These Instruments result from an investigation notified by the Authority in the
Government Notices Gazette of 31 October 2012 concerning mesothelioma in
accordance with section 196G of the VEA. The investigation involved an examination of
the sound medical-scientific evidence now available to the Authority, including the
sound medical-scientific evidence it has previously considered.
The contents of these Instruments are in similar terms as the revoked Instruments. Comparing
these Instruments and the revoked Instruments, the differences include:
For RH SoP (Instrument No. 104/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the definition of 'mesothelioma' in subsection 7(2);
 new factor in subsection 9(2) concerning 'talc containing asbestiform fibres;
 revising the factor in subsection 9(4) concerning 'ionising radiation';
 new factor in subsection 9(6) concerning 'firefighting';
 new definitions of 'asbestiform', 'cumulative equivalent dose', 'firefighting', 'MRCA', 'talc
containing asbestiform fibres' and 'VEA' in Schedule 1 - Dictionary;
 revising the definition of 'relevant service' in Schedule 1 – Dictionary.
For BoP SoP (Instrument No. 105/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the definition of 'mesothelioma' in subsection 7(2);
 revising the factor in subsection 9(4) concerning 'ionising radiation';
 new factor in subsection 9(6) concerning 'firefighting';
 new definitions of 'cumulative equivalent dose', 'firefighting', 'MRCA' and 'VEA' in
Schedule 1 - Dictionary;
 revising the definition of 'relevant service' in Schedule 1 – Dictionary.
The determining of these Instruments finalises the investigation in relation to
mesothelioma as advertised in the Government Notices Gazette of 31 October 2012.
These Instruments result from an investigation notified by the Authority in the
Government Notices Gazette of 31 October 2012 concerning ingrowing nail in
accordance with section 196G of the VEA. The investigation involved an examination of
the sound medical-scientific evidence now available to the Authority, including the
sound medical-scientific evidence it has previously considered.
SUMMARY OF CHANGES
The contents of these Instruments are in similar terms as the revoked Instruments. Comparing
these Instruments and the revoked Instruments, the differences include:
For RH SoP (Instrument No. 106/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the definition of 'ingrowing nail' in subsection 7(2);
 revising the factor in subsection 9(1) concerning 'an acquired deformity of the affected
digit, affected nail or the affected nail bed';
 revising factors in subsections 9(2) & 9(6) concerning 'an injury to the affected nail or the
affected nail bed';
 revising factors in subsections 9(3) & 9(7) concerning 'an epidermal growth factor
receptor inhibitor or antiviral treatment with indinavir';
 revising factors in subsections 9(4)(a) & 9(8)(a) concerning 'poor nail care', for ingrowing
toenail only;
 revising the factor in subsection 9(8)(b) concerning 'poor foot hygiene', for ingrowing
toenail only and for clinical worsening only;
 new factors in subsections 9(4)(c) & 9(8)(d) concerning 'hyperhydrosis', for ingrowing
toenail only;
 new factors in subsections 9(4)(d) & 9(8)(e) concerning 'an inability to keep the skin of
the feet dry', for ingrowing toenail only;
 new factor in subsection 9(8)(f) concerning 'diabetes mellitus or atherosclerotic peripheral
vascular disease', for ingrowing toenail only and for clinical worsening only;
 new factors in subsections 9(5) & 9(9) concerning 'fungal infection involving the affected
nail';
 new definitions of 'deformity of the affected digit, affected nail or the affected nail bed',
'MRCA', 'poor nail care of the affected toenail' and 'VEA' in Schedule 1 - Dictionary;
 revising the definitions of 'ill-fitting footwear', 'poor foot hygiene' and 'relevant service'
in Schedule 1 - Dictionary; and
 deleting the definitions of 'a deformity of the affected digit or the affected nail bed' and
'poor nail care'.
For BoP SoP (Instrument No. 107/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the definition of 'ingrowing nail' in subsection 7(2);
 revising the factor in subsection 9(1) concerning 'an acquired deformity of the affected
digit, affected nail or the affected nail bed';
 revising factors in subsections 9(2) & 9(6) concerning 'an injury to the affected nail or the
affected nail bed';
 revising factors in subsections 9(3) & 9(7) concerning 'an epidermal growth factor
receptor inhibitor or antiviral treatment with indinavir';
 revising factors in subsections 9(4)(a) & 9(8)(a) concerning 'poor nail care', for ingrowing
toenail only;
 revising the factor in subsection 9(8)(b) concerning 'poor foot hygiene', for ingrowing
toenail only and for clinical worsening only;
 new factors in subsections 9(4)(c) & 9(8)(d) concerning 'hyperhydrosis', for ingrowing
toenail only;
 new factors in subsections 9(4)(d) & 9(8)(e) concerning 'an inability to keep the skin of
the feet dry', for ingrowing toenail only;
 new factors in subsections 9(5) & 9(9) concerning 'fungal infection involving the affected
nail';
 new definitions of 'deformity of the affected digit, affected nail or the affected nail bed',
'MRCA', 'poor nail care of the affected toenail' and 'VEA' in Schedule 1 - Dictionary;
 revising the definitions of 'ill-fitting footwear', 'poor foot hygiene' and 'relevant service'
in Schedule 1 - Dictionary; and
 deleting the definitions of 'a deformity of the affected digit or the affected nail bed' and
'poor nail care'.
The determining of these Instruments finalises the investigation in relation to
ingrowing nail as advertised in the Government Notices Gazette of 31 October 2012.
Page 8 of 11
SUMMARY OF CHANGES
108 &
109/2015
110 &
111/2015
Meniere's
disease
external burn
These Instruments result from an investigation notified by the Authority in the
Government Notices Gazette of 2 May 2012 concerning Meniere's disease in accordance
with section 196G of the VEA. The investigation involved an examination of the sound
medical-scientific evidence now available to the Authority, including the sound medicalscientific evidence it has previously considered.
The contents of these Instruments are in similar terms as the revoked Instruments. Comparing
these Instruments and the revoked Instruments, the differences include:
For RH SoP (Instrument No. 108/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the factor in subsection 9(1) concerning 'a moderate to severe traumatic brain
injury';
 revising the factor in subsection 9(2) concerning 'otitis media';
 new factor in subsection 9(4) concerning 'autoimmune diseases';
 new definitions of 'MRCA', 'specified list of autoimmune diseases' and 'VEA' in Schedule
1 - Dictionary;
 revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
 deleting the definition of 'head injury'.
For BoP SoP (Instrument No. 109/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the factor in subsection 9(1) concerning 'a moderate to severe traumatic brain
injury';
 new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
 revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
 deleting the definition of 'head injury'.
The determining of these Instruments finalises the investigation in relation to
Meniere's disease as advertised in the Government Notices Gazette of 2 May 2012.
These Instruments result from an investigation notified by the Authority in the
Government Notices Gazette of 2 November 2011 concerning external burn in
accordance with section 196G of the VEA. The investigation involved an examination of
the sound medical-scientific evidence now available to the Authority, including the
sound medical-scientific evidence it has previously considered.
The contents of these Instruments are in similar terms as the revoked Instruments. Comparing
these Instruments and the revoked Instruments, the differences include:
For RH SoP (Instrument No. 110/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
 specifying a day of commencement for the Instrument in section 2;
 revising the definition of 'external burn' in subsection 7(2);
 revising the factor in subsection 9(1) concerning 'a heat source';
 revising the factor in subsection 9(2) concerning 'extreme cold';
 revising the factor in subsection 9(3) concerning 'vesicant or corrosive chemicals';
 revising the factor in subsection 9(4) concerning 'ionising radiation';
 revising the factor in subsection 9(5) concerning 'radiofrequency or microwave radiation';
 revising the factor in subsection 9(6) concerning 'infrared radiation';
 revising the factor in subsection 9(7) concerning 'laser';
 revising the factor in subsection 9(8) concerning 'ultraviolet radiation';
 revising the factor in subsection 9(9) concerning 'high intensity focussed ultrasound';
 deleting a factor concerning 'friction' which is now covered by a factor in the Reasonable
Hypothesis Statement of Principles concerning cut, stab, abrasion and laceration;
 deleting a factor concerning 'electric shock or lightning' which is now covered by a factor
in the Reasonable Hypothesis Statement of Principles concerning electrical injury;
 new definitions of 'extreme cold', 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and
 revising the definitions of 'cumulative equivalent dose' and 'relevant service' in Schedule
1 – Dictionary.
For BoP SoP (Instrument No. 111/2015)
 adopting the latest revised Instrument format, which commenced in 2015;
Page 9 of 11
SUMMARY OF CHANGES












specifying a day of commencement for the Instrument in section 2;
revising the definition of 'external burn' in subsection 7(2);
revising the factor in subsection 9(1) concerning 'a heat source';
revising the factor in subsection 9(2) concerning 'extreme cold';
revising the factor in subsection 9(3) concerning 'vesicant or corrosive chemicals';
revising the factor in subsection 9(4) concerning 'ionising radiation';
revising the factor in subsection 9(5) concerning 'radiofrequency or microwave radiation';
revising the factor in subsection 9(6) concerning 'infrared radiation';
revising the factor in subsection 9(7) concerning 'laser';
revising the factor in subsection 9(8) concerning 'ultraviolet radiation';
revising the factor in subsection 9(9) concerning 'high intensity focussed ultrasound';
deleting a factor concerning 'friction' which is now covered by a factor in the Balance of
Probabilities Statement of Principles concerning cut, stab, abrasion and laceration;
 deleting a factor concerning 'electric shock or lightning' which is now covered by a factor
in the Balance of Probabilities Statement of Principles concerning electrical injury;
 new definitions of 'extreme cold', 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and
 revising the definitions of 'cumulative equivalent dose' and 'relevant service' in Schedule
1 – Dictionary.
On 28 April 2015, the Authority wrote to organisations representing veterans, service
personnel and their dependants regarding the proposed Instruments and the medical-scientific
material considered by the Authority. This letter emphasised the deletion of factors relating
to friction and electric shock or lightening. These factors are now covered by other
Statements of Principles. The Authority provided an opportunity to the organisations to make
representations in relation to the proposed Instruments prior to their determination. No
submissions were received for consideration by the Authority. Minor changes were made to
the content of the proposed Instruments following this consultation process, as a revised
Instrument format was applied.
112 &
113/2015
hepatitis E
The determining of these Instruments finalises the investigation in relation to external
burn as advertised in the Government Notices Gazette of 2 November 2011.
These Instruments result from an investigation notified by the Authority in the
Government Notices Gazette of 2 May 2012 concerning hepatitis E in accordance with
section 196G of the VEA. The investigation involved an examination of the sound
medical-scientific evidence now available to the Authority, including the sound medicalscientific evidence it has previously considered.
The contents of these Instruments are in similar terms as the revoked Instruments. Comparing
these Instruments and the revoked Instruments, the differences include:
For RH & BoP SoPs (Instrument Nos. 112 & 113/2015)

adopting the latest revised Instrument format, which commenced in 2015;

specifying a day of commencement for the Instrument in section 2;

revising the definition of 'hepatitis E' in subsection 7(2);

revising the factor in subsection 9(1) concerning 'being exposed to the hepatitis E
virus';

deleting a factor concerning 'being pregnant';

new definitions of 'MRCA' and 'VEA' in Schedule 1 – Dictionary; and

revising the definitions of 'being exposed to the hepatitis E virus' and 'relevant
service' in Schedule 1 – Dictionary.
On 28 April 2015, the Authority wrote to organisations representing veterans, service
personnel and their dependants regarding the proposed Instruments and the medical-scientific
material considered by the Authority. This letter emphasised the deletion of factors relating
to being pregnant. The Authority provided an opportunity to the organisations to make
representations in relation to the proposed Instruments prior to their determination. No
submissions were received for consideration by the Authority. Minor changes were made to
the content of the proposed Instruments following this consultation process, as a revised
Instrument format was applied.
The determining of these Instruments finalises the investigation in relation to
hepatitis E as advertised in the Government Notices Gazette of 2 May 2012.
Page 10 of 11
SUMMARY OF CHANGES
114 &
115/2015
lipoma
Amendments
These instruments amend Statements of Principles Nos. 100 & 101 of 2015, concerning
lipoma by:
RH & BoP Amendment SoPs (Instrument No. 114 & 115/2015)

removing the phrase "in superficial subcutaneous tissues" in subsection 7(2)(a).
These amendments are made to rectify a clerical error identified after the lodgement of
Statements of Principles Nos. 100 & 101 of 2015.
Page 11 of 11